Alkermes Plc (ALKS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Alkermes Plc stock (ALKS) is currently trading at $28.40. Alkermes Plc PE ratio is 19.86. Alkermes Plc PS ratio (Price-to-Sales) is 3.21. Analyst consensus price target for ALKS is $43.65. WallStSmart rates ALKS as Underperform.
- ALKS PE ratio analysis and historical PE chart
- ALKS PS ratio (Price-to-Sales) history and trend
- ALKS intrinsic value — DCF, Graham Number, EPV models
- ALKS stock price prediction 2025 2026 2027 2028 2029 2030
- ALKS fair value vs current price
- ALKS insider transactions and insider buying
- Is ALKS undervalued or overvalued?
- Alkermes Plc financial analysis — revenue, earnings, cash flow
- ALKS Piotroski F-Score and Altman Z-Score
- ALKS analyst price target and Smart Rating
Alkermes
📊 No data available
Try selecting a different time range
ALKS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Alkermes Plc (ALKS)
ALKS trades 259% above its Graham fair value of $9.72, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Alkermes Plc (ALKS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in profit margin, institutional own.. Concerns around revenue growth and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Alkermes Plc (ALKS) Key Strengths (3)
110.30% of shares held by major funds and institutions
Strong profitability: $16 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Alkermes Plc (ALKS) Areas to Watch (7)
Revenue declining -10.60%, a shrinking business
Earnings declining -67.00%, profits shrinking
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 3.21x sales
Fairly priced relative to book value
Supporting Valuation Data
Alkermes Plc (ALKS) Detailed Analysis Report
Overall Assessment
This company scores 53/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.3/10) while 7 fall into concern territory (avg 4.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Profit Margin, Market Cap. Profitability is solid with Profit Margin at 16.40%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Return on Equity. Some valuation metrics including PEG Ratio (1.96), Price/Sales (3.21), Price/Book (2.54) suggest expensive pricing. Growth concerns include Revenue Growth at -10.60%, EPS Growth at -67.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 14.70%, Operating Margin at 15.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 14.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -10.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Profit Margin) and negatives (Revenue Growth, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ALKS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ALKS's Price-to-Sales ratio of 3.21x trades at a deep discount to its historical average of 10.32x (2th percentile). The current valuation is 85% below its historical high of 22.02x set in Dec 2014, and 3% above its historical low of 3.12x in Mar 2026.
Compare ALKS with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Alkermes Plc (ALKS) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Alkermes Plc faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 1.5B with 11% decline year-over-year. Profit margins of 16.4% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 1470.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 170M in free cash flow and 170M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 11% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Alkermes Plc.
Bottom Line
Alkermes Plc faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Alkermes Plc(ALKS)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.